SCHEMBL29614929

SCHEMBL29614929

C#Cc1ccc(C(=O)N2CCCCC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.71
ALDH1A1 P00352 4/20 0.71
MEN1 O00255 1/20 0.56
TSHR P16473 1/20 0.56
KMT2A Q03164 1/20 0.56
MAPK1 P28482 1/20 0.54
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
MLYCD O95822 2/20 0.53
USP2 O75604 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
MAPT P10636 1/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
MBTD1 Q05BQ5 3/20 0.51
L3MBTL3 Q96JM7 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19891353 0.85 L3MBTL3 (0.78) ALDH1A1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL7132525 0.84 HPGD (1.00) HPGDALDH1A1MEN1TSHRKMT2A
SCHEMBL27479149 0.84 HPGD (1.00) HPGDALDH1A1MEN1TSHRKMT2A
SCHEMBL21078241 0.83 L3MBTL3 (0.55) HPGDALDH1A1MEN1TSHRKMT2A
SCHEMBL14661704 0.83 GRM5 (0.68) HPGDMEN1TSHRKMT2AL3MBTL1
SCHEMBL166200 0.83 PHGDH (0.63) HPGDALDH1A1TSHRKMT2AMAPK1
SCHEMBL10721733 0.82 HPGD (0.95) HPGDALDH1A1MEN1TSHRKMT2A
SCHEMBL3633068 0.82 HPGD (0.71) HPGDALDH1A1MEN1TSHRKMT2A
SCHEMBL6553708 0.81 HPGD (0.70) HPGDALDH1A1MEN1TSHRKMT2A
SCHEMBL4099294 0.81 GRM5 (0.68) HPGDALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312348-B2 RET inhibitors, pharmaceutical compositions and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2025-05-27 US disclosed
CN-111285874-B RET inhibitor, pharmaceutical composition thereof and application thereof 广东东阳光药业股份有限公司 2024-08-09 CN disclosed
US-20220119382-A1 RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119382-A1 RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF RET, SLC10A2, REL HPGD 1438/4885ALDH1A1 2416/4885MEN1 183/4885
US-12312348-B2 RET inhibitors, pharmaceutical compositions and uses thereof RET, SLC10A2, REL HPGD 1438/4885ALDH1A1 2416/4885MEN1 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.